Phase II study of using Carbamazepine for neurosensory toxicity related FOLFOX regimens in patients with advanced/recurrent colorectal cancer (OGSG 0603)

Interventions: Carbamazepin is administered during FOLFOX therapy. Carbamazepin tablet 100mg, 200mg or granule including Car. 500mg in 1000mg Primary outcome(s): To test the feasibility of Carmazepin therapy and to evaluate whether Carmazepin has the protective and/or prophylactic effects against peripheral nerve syndrome due to FOLFOX therapy Study Design: Single arm Non-randomized